drugset / Trial / NCT00729443

Investigating Safety, Tolerability and Pharmakinetics When Giving Single and Fractionated Doses of AZD3241 to Healthy Volunteers

NCT00729443

Phase 1 Completed 64 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The study is carried out in order to investigate safety, tolerability and pharmacokinetics after administrating single and fractionated doses of AZD3241 to healthy volunteers

Timeline

Start
2008-07
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Verdiperstat Small molecule Oral

Indications

No indication recorded.